

AUM

November 2025

INR 2,010.77 Cr.

Investment Objective

To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.

Why Invest in HDFC Pharma and Healthcare Fund?

- Domestic healthcare spends to increase due to rising longevity, low penetration and growing elderly population
- Rising chronic diseases to result in repeated buying and higher margins for pharma companies
- Growing share of Indian companies in US generics, improved pricing erosion environment and large chunk of drugs going off-patent over the next few years provides a big opportunity for Indian pharma companies
- Biosimilars - an untapped long-term growth lever for Indian pharma companies
- Indian pharma companies are now playing pivotal role in driving global innovation through the CDMO* route
- Manufacturing Leadership - India has the second highest share of USFDA approved facilities; the manufacturing competitiveness has improved further with introduction of PLI scheme and low labour cost.

*CDMO - Contract Development and Manufacturing Organization. Source: USFDA - United States Food and Drug Administration.

Top 10 Equity Holdings (as on 30th November, 2025)

Company	Industry*	% to NAV
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Biotechnology	11.34
Divis Laboratories Ltd.	Pharmaceuticals & Biotechnology	8.34
Lupin Ltd.	Pharmaceuticals & Biotechnology	6.4
Glenmark Pharmaceuticals Ltd.	Pharmaceuticals & Biotechnology	6.09
Max Healthcare Institute Limited	Healthcare Services	6.07
Alkem Laboratories Ltd.	Pharmaceuticals & Biotechnology	5.89
Ipca Laboratories Ltd.	Pharmaceuticals & Biotechnology	4.61
Laurus Labs Ltd.	Pharmaceuticals & Biotechnology	4.02
Anthem Biosciences Limited	Pharmaceuticals & Biotechnology	3.89
Torrent Pharmaceuticals Ltd.	Pharmaceuticals & Biotechnology	3.71

* Industry classification as recommended by AMFI. For complete portfolio details please refer to the website www.hdfcfund.com

Quantitative Data (Risk Ratios)

Standard Deviation	16.333%
Beta	0.987
Sharpe Ratio*	1.450

Computed for the 3 - year period ended November 30, 2025. Based on month end NAV. * Risk free Rate: 5.59% (Source: FIMMDA MIBOR)

Portfolio Turnover Ratio

Equity Turnover 34.81%
Total Turnover 34.81%
Total Turnover = Equity + Debt + Derivative

Market Cap Segment wise Exposure

	June 2025	July 2025	Aug 2025	Sep 2025	Oct 2025	Nov 2025
Large Cap	32.4%	38.0%	39.0%	37.8%	38.2%	38.8%
Mid Cap	25.4%	20.2%	24.3%	26.2%	25.3%	27.0%
Small Cap	40.1%	40.0%	35.6%	34.9%	34.7%	32.6%

% of Net Assets (As per AMFI classification as on December 2024)

Fund Facts

Category of Scheme	Sectoral Fund
Fund Manager*	Nikhil Mathur (since October 4, 2023)
Inception Date	October 4, 2023
Benchmark	BSE Healthcare Index (Total Return Index)
Investment Plans / Options	Regular Plan, Direct Plan. Under Each Plan: Growth & IDCW Option. The IDCW Option offers following Sub-Options: Payout of IDCW Option; and Reinvestment of IDCW Option.
\$\$ Exit Load	<ul style="list-style-type: none"> In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed/switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched-out after 30 days from the date of allotment.


*Dedicated Fund Manager for Overseas Investments: Mr. Dhruv Muchhal (since October 4, 2023)

What's In What's Out (30th November vs 31st October 2025)

Entry		Exit	
Company Name	Industry	Company Name	Industry
Global Health Ltd.	Healthcare Services	Fortis Healthcare Ltd.	Healthcare Services

Increased Exposure		Decreased Exposure	
Company Name	Industry	Company Name	Industry
Anthem Biosciences Ltd.	Pharmaceuticals & Biotechnology	Piramal Pharma Ltd.	Pharmaceuticals & Biotechnology
Max Healthcare Institute Ltd.	Healthcare Services	Lupin Ltd.	Pharmaceuticals & Biotechnology
Shilpa Medicare Ltd.	Pharmaceuticals & Biotechnology	Gland Pharma Ltd.	Pharmaceuticals & Biotechnology
Ajanta Pharmaceuticals Ltd.	Pharmaceuticals & Biotechnology		

Product Labelling and Riskometer

This product is suitable for investors who are seeking*	Riskometer#
<ul style="list-style-type: none"> To generate long-term capital appreciation Investment predominantly in equity & equity related instruments of Pharma and healthcare companies. <p>* Investors should consult their financial advisers, if in doubt about whether the product is suitable for them.</p>	 <p>RISKOMETER The risk of the scheme is very high</p>

For latest Riskometer, investors may refer to the Monthly Portfolios disclosed on the website of the Fund viz. www.hdfcfund.com
Scheme riskometer as of November 30, 2025

The Scheme being sectoral in nature carries higher risks versus diversified equity mutual funds on account of concentration and sector specific risks.

Stocks/Sectors/Themes referred should not be construed as an investment advice or a recommendation by HDFC Mutual Fund ("the Fund") / HDFC AMC to buy or sell the stock or any other security covered under the respective sector/stocks/themes. The Fund may or may not have any present or future positions in these stocks/sectors/themes.

\$\$ Exit Load: (i) No Exit Load shall be levied for switching between Plans / Options within the Scheme. However, exit load will be applicable if the units are switched-out / redeemed from the Scheme within the exit load period from the initial date of purchase. (ii) Switch of investments between Plans under a Scheme having separate portfolios, will be subject to applicable exit load. (iii) No exit load will be levied on Bonus Units and Units allotted on IDCW Re-investment. (iv) The exit load levied on redemption/switch-out will be the load prevailing 1. In case of lumpsum transactions, on the date of allotment of units 2. In case of Systematic Transactions such as SIP, STP etc., on the date of registration / enrolment.